Jaber, Samir
Monnin, Marion
Girard, Mehdi
Conseil, Matthieu
Cisse, Moussa
Carr, Julie
Mahul, Martin
Delay, Jean Marc
Belafia, Fouad
Chanques, Gérald
Molinari, Nicolas
De Jong, Audrey
Funding for this research was provided by:
Centre Hospitalier Régional Universitaire de Montpellier
Article History
Received: 9 September 2016
Accepted: 4 October 2016
First Online: 11 October 2016
Compliance with ethical standards
:
: Dr. Jaber reports receiving consulting fees from Drager, Hamilton, Maquet, and Fisher & Paykel. No potential conflict of interest relevant to this article was reported for the other authors.
: The study is an investigator-initiated trial. Study promoter is Montpellier University Hospital, Montpellier, France. There is no industry support or involvement in the trial. The funder had no role in the design or conduct of the study, data collection, analysis or interpretation, the writing of the report or in the decision to submit for publication. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
: Full protocol was published in BMJ Open Access [CitationRef removed] and follows Consort 2010 guidelines.
: The Institutional Review Board of the University Hospital of Montpellier (France) approved the trial. On 13 May 2015, the study was approved by a central ethics committee (Comité de Protection des Personnes Sud-Méditerranée IV, Montpellier, France) with the registration number IDRCB 2015-A00708-41. The OPTINIV study was conducted in accordance with the Declaration of Helsinki and was registered at ExternalRef removed with trial identification number NCT02530957.
Free to read: This content has been made available to all.